Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23324916 | 0.81 | BCHE (0.38) | DPP4BCHE | |
| SCHEMBL21787567 | 0.81 | BCHE (0.32) | BCHE | |
| SCHEMBL27324176 | 0.79 | ALDH1A1 (0.33) | ALDH1A1GAAKMT2ABCHECTSB | |
| SCHEMBL27324174 | 0.78 | ALDH1A1 (0.32) | ALDH1A1GAAKMT2ABCHECTSB | |
| SCHEMBL2904019 | 0.76 | TLR2 (0.33) | DPP4 | |
| SCHEMBL2904021 | 0.76 | TLR2 (0.33) | DPP4 | |
| SCHEMBL2904022 | 0.76 | TLR2 (0.33) | DPP4 | |
| SCHEMBL13404483 | 0.76 | GABRR1 (0.39) | ALDH1A1GAAKMT2A | |
| SCHEMBL21776710 | 0.76 | GABRR1 (0.39) | ALDH1A1GAAKMT2A | |
| SCHEMBL19655789 | 0.76 | GABRR1 (0.39) | ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |